Clinical Trial Update: A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of MRG004A in patients with tissue factor–positive advanced or metastatic solid tumors (sponsor: Shanghai Miracogen).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Metastatic Solid Tumors

Drugs mentioned

• MRG004A

Snippet

Sponsor: Shanghai Miracogen Inc. | Conditions: Advanced or Metastatic Solid Tumors | Phase 1, Phase 2 | Status: UNKNOWN